Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN11946807
ISRCTN11946807
Completed
未知

ongitudinal study of physiological and immunological responses to COVID-19/SARS-CoV-2 infection in a population based study – Children of the 90s

niversity of Bristol0 sites372 target enrollmentNovember 23, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCOVID-19 (SARS-CoV-2 infection)Infections and Infestations

Overview

Phase
未知
Intervention
Not specified
Conditions
COVID-19 (SARS-CoV-2 infection)
Sponsor
niversity of Bristol
Enrollment
372
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 23, 2020
End Date
November 30, 2021
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
niversity of Bristol

Eligibility Criteria

Inclusion Criteria

  • •Participants of the ALSPAC cohort meeting the following criteria:
  • •1\. Aged 25 or over
  • •2\. Undergone SARS\-CoV\-2 antibody testing through the ALSPAC SARS\-CoV\-2 serology study (IRAS 289493\)
  • •3\. Individuals who, through self\-report or through linkage to official health records, are identified as being highly likely to have had COVID\-19 infection (from either positive SARS\-CoV\-2 PCR test performed at NHS care facility, COVID\-19 testing site or home testing)
  • •4\. Individuals who have been told by a physician that, in the opinion of that doctor, they have had a clinical illness likely to be COVID\-19
  • •Control participants
  • •5\. Aged 25 or over
  • •6\. Individuals who self\-report as not experiencing symptoms of COVID\-19 via the symptom survey
  • •7\. Self\-report as not having had positive SARS\-CoV\-2 molecular test
  • •8\. Are confirmed SARS\-CoV\-2 seronegative at Visit 1

Exclusion Criteria

  • •Exclusion criteria for both controls and cases:
  • •1\. Do not wish to participate in this research study
  • •2\. Participants taking blood thinners or blood\-thinning agents (e.g. warfarin) or with a known clotting disorder or other reason unable to provide a blood sample
  • •3\. Not willing to provide blood samples
  • •4\. Do not meet eligibility criteria for respective arm

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A study of biological, immunological and physiological parameters describing skin irritation induced by a physical stimulus in healthy male volunteersskin irritation10014982
NL-OMON38828TNO30
Recruiting
Not Applicable
ongitudinal study of immune response and epigenetics in acute LongCovid syndrome secondary to COVID-19 disease.post-COVID-19 syndromeU09.9Post COVID-19 condition, unspecified
DRKS00027314Klinik I für Innere MedizinUniversitätsklinikum Köln (AöR)100
Not yet recruiting
Not Applicable
Research for the Clinical Effect and Immune Mechanism of Soothing the Lung and Anti-fever, Resolving Blood-stasis and Unblocking Collaterals in the Treatment of Mycoplasma Pneumoniae Pneumonia in Childre
ITMCTR1900002294First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Active, not recruiting
Phase 1
A study to investigate the clinical and immunological effects on field cancerization in patients treated with PD-1 inhibition for advanced or metastatic cutaneous squamous cell carcinomaadvanced or metastatic cutaneous squamous cell carcinomaMedDRA version: 24.1Level: LLTClassification code 10085908Term: Cutaneous squamous cell carcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2021-006372-17-DEMuehlenkreiskliniken AoeR20
Completed
Not Applicable
Clinical and immunological analysis on the effect of LEM in the adoptive immunotherapy using autologous activated lymphocytes in patients with incurable cancerIncurable cancer
JPRN-UMIN000012283Kawasaki Medical School20